410 Non-Invasive Diagnosis of Prostate Cancer from Body Fluids Using a Panel of Tumor Suppressor Genes (original) (raw)

2011, European Urology Supplements

Eur Urol Suppl 2011;10(2):143 results: The median of follow-up was 42.9 months (27.14-49.5). Patients with MPC had significantly higher CTC levels [m: 18.5 (1-126)] compared with the other two groups (P < 0.001). A significant positive correlation was demonstrated (P < 0.001) between CTC levels and all tumour burden markers: PSA (Rho = 0.55), T (Tau = 0.47), N (m N1: 18.5, m N0: 0.0) and M ( Tau = 0.54) except Gleason score(Tau = 0.16). The overall survival to 6, 12 and 18 months was 80 %, 69 % and 62 % respectively. The progression-free survival to 6, 12 and 18 months was 76 %, 46 % and 33 % respectively. A cut-off level ≥ 4 CTC (S: 90 %; E: 87.6 %) was chosen to distinguish patients with an unfavorable prognosis. These patients had a significantly shorter median overall and progression-free survival (P < 0.001). As the CTC levels were increasing, the overall survival and progression-free survival decreased. The risk of mortality and progression for the patients with ≥ 4 CTC was 4.1 (IC 95 %: 1.1-14.6; P = 0.029) and 8.5 (IC 95 %: 2.6-26.9; P < 0.001) times higher. Using a multivariate piecewise Cox regression mode, the level of ≥ 4 CTC was an independent predictor of PSA relapse (HR: 5,9; IC 95 %: 1,(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)4; p <0,005). Conclusions: The immunomagnetic analysis allows us to quantify the CTC in peripheral blood and could provide a possibility for correctly staging and to estimate the prognostic value of the metastatic hormone-sensitive prostate cancer with the purpose of the early onset of new therapies.

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact